FDA — authorised 20 May 2024
- Application: BLA761350
- Marketing authorisation holder: SAMSUNG BIOEPIS CO LTD
- Local brand name: OPUVIZ
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA authorised OPUVIZ on 20 May 2024
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 20 May 2024; FDA has authorised it.
SAMSUNG BIOEPIS CO LTD holds the US marketing authorisation.